既往接种重组水疱性口炎病毒-扎伊尔埃博拉病毒疫苗与埃博拉病毒感染患者生存改善相关
在刚果民主共和国东部布滕博和卡图瓦的埃博拉治疗中心,对2019年3月30日至8月10日收治的257例确诊埃博拉病毒病患者进行回顾性观察研究,其中44例入院前已接种rVSV-ZEBOV疫苗、213例未接种。接种者入院时病毒载量较低、急性肾损伤较少、死亡风险较低,提示既往接种与感染严重程度降低和生存改善相关。
要点
- 接种组入院时病毒载量6.0 log10 cp/mL低于未接种组6.9 log10 cp/mL(p=0.017)。
- 接种组急性肾损伤风险低于未接种组(OR 0.44,95%CI 0.20-0.94,p=0.027)。
- 接种组死亡10/44(23%)低于未接种组117/213(55%)(OR 0.24,95%CI 0.11-0.51,p<0.001)。
核心结论
- 既往接种rVSV-ZEBOV疫苗与埃博拉病毒病感染严重程度降低和生存改善相关。
- 这些发现支持rVSV-ZEBOV疫苗在调节埃博拉病毒病严重程度方面的效力。
研究设计与样本
- 回顾性观察研究,纳入2019年3月30日至8月10日刚果民主共和国东部布滕博和卡图瓦埃博拉治疗中心收治的257例患者。
- 44例入院前已接种rVSV-ZEBOV疫苗,213例未接种。
主要发现
- 接种组入院时间中位2天(IQR 1.8-4)早于未接种组4天(IQR 3-6),p<0.001。
- 接种组入院时病毒载量6.0 log10 cp/mL(IQR 5.0-7.1)低于未接种组6.9 log10 cp/mL(IQR 5.4-7.6),p=0.017。
- 纵向分析中,接种组总体病毒血症较未接种组低1.32 log10 cp/mL(95%CI 0.58-2.1)。
- 接种组入院时急性肾损伤风险低于未接种组(OR 0.44,95%CI 0.20-0.94,p=0.027)。
- 接种组死亡10/44(23%)低于未接种组117/213(55%)(OR 0.24,95%CI 0.11-0.51,p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The second largest Ebolavirus disease (EVD) outbreak ever recorded is currently ongoing in Eastern Democratic Republic of the Congo (DRC). This is the first outbreak for which the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus (rVSV-ZEBOV) candidate vaccine has been widely administered, using a ring vaccination strategy. We examined whether prior vaccination with rVSV-ZEBOV impacts viral load, organ impairment, and survival among patients with EVD admitted to Ebola Treatment Units (ETUs) in the DRC. We conducted a retrospective observational study of patients admitted to the ETUs in Butembo and Katwa, Eastern DRC, between 30 March and 10 August 2019. We included 257 patients, of whom 44 had been vaccinated prior to admission and 213 were unvaccinated. Vaccinated patients were admitted to hospital sooner than unvaccinated patients (median 2 days (IQR 1.8-4) versus 4 days (IQR 3-6), p < 0.001). Vaccinated patients had a lower viral load at admission compared to those who were unvaccinated: 6.0 log10 cp/mL (IQR 5.0-7.1) versus 6.9 log10 cp/mL (IQR 5.4-7.6), p = 0.017. In a longitudinal analysis of daily viral load measurements, vaccinated patients had an overall viremia 1.32 log10 cp/mL (95% CI 0.58-2.1) lower than unvaccinated patients over the course of their infection. Acute kidney injury at admission was less common in vaccinated patients: OR 0.44 (95% CI 0.20-0.94), p = 0.027. Mortality in vaccinated patients was 10/44 (23%) compared to 117/213 (55%) unvaccinated patients (OR 0.24, 95% CI 0.11-0.51, p < 0.001). In conclusion, prior rVSV-ZEBOV vaccination was associated with reduced severity of infection and improved survival among patients with confirmed EVD treated at ETUs in Eastern DRC. These findings support the efficacy of the rVSV-ZEBOV vaccine in modulating EVD severity.
引用
- Kasereka MC, Ericson AD, Conroy AL, et al. Prior vaccination with recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus vaccine is associated with improved survival among patients with Ebolavirus infection. Vaccine. 2020. PMID: 32093984. doi:10.1016/j.vaccine.2020.02.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。